We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Amgen (AMGN) to Report Q1 Earnings: What's in the Cards?
Read MoreHide Full Article
Amgen, Inc. (AMGN - Free Report) will report first-quarter 2021 results on Apr 27, after market close. In the last reported quarter, the company delivered an earnings surprise of 13.39%.
The large biotech’s performance has been pretty impressive, with earnings beating estimates in each of the trailing four quarters. The company delivered a four-quarter earnings surprise of 13.54%, on average.
Amgen’s stock has risen 11% this year so far against a decrease of 2% for the industry.
Factors to Consider
Historically, the first quarter of 2021 represents the lowest product sales quarter of the year for Amgen as U.S. patients work through deductibles, especially for products, including Enbrel, Otezla and Aimovig.
The first quarter of 2020 had benefited from roughly $100 million in inventory build due to COVID-19, which was absent in the first quarter of 2021. Nonetheless, in the first quarter, volume growth from Prolia, Otezla Repatha, Evenity, Aimovig, and Amgen’s biosimilars portfolio is expected to have been partially offset by biosimilar/generic competition for mature drugs and accelerating erosion in U.S. Parsabiv sales due to changes in reimbursement rules for the drug.
In the second half of 2020, Amgen experienced recovery from peak impact of the COVID-19 pandemic as physician interaction and prescription trends of several drugs like Prolia and Xgeva improved. Though the recovery is expected to have continued in the first quarter, the impact of rising COVID-19 infection rates is to be seen.
Meanwhile, higher volumes may have benefited sales of Blincyto, Nplate, Repatha, Vectibix Otezla and Evenity.
New patient share helped by encouraging uptake for combination use of Kyprolis plus Darzalex and dexamethasone (based on CADOR study data) might have pulled up sales of Kyprolis. Parsabiv sales in the first quarter are expected to be the lowest of the year as customers depleted inventory build in the second half of 2020.
The Zacks Consensus Estimate for Prolia is $701 million, Xgeva is $485 million, Blincyto is $103 million, Parsabiv is $116 million, Repatha is $244 million, Kyprolis is $277 million and Otezla is $585 million.
Also, increasing branded and generic competition for its legacy products like Enbrel, Aranesp, Epogen, Neupogen, Neulasta and Sensipar are likely to have hurt the top line. In the first quarter of 2020, Enbrel benefited from approximately $115 of favorable changes to estimated sales deductions, which will not reflect and thereby hurt results of the first quarter of 2021. The Zacks Consensus Estimate for Enbrel is $1.10 billion.
For biosimilars, volume growth may have been partially offset by lower prices due to increased competition. Market expansion and volume growth are expected to benefit Mvasi’s (biosimilar of Roche’s [(RHHBY - Free Report) ] Avastin) sales while lower prices due to increased competition may hurt sales. Kanjinti’s (Amgen’s biosimilar of Roche’s Herceptin) sequential sales may have declined, similar to the fourth quarter of 2020, as volume gains might have been offset by price declines
Meanwhile, in December, the FDA approved Riabni, a biosimilar to Roche’s Rituxan. Amgen may report first sales from the biosimilar product in the first quarter.
Investments in innovation, launch of new products and digitization efforts are expected to have increased operating expenses in the first quarter.
Key Development in the Quarter
In March, Amgen announced an agreement to acquire small biotech, Five Prime Therapeutics or $38.00 per share in cash (an equity value of approximately $1.9 billion) to strengthen its oncology portfolio. The acquisition will add the latter’s lead pipeline candidate, bemarituzumab, a first-in-class, phase III ready, anti-FGFR2b antibody, to its portfolio. The transaction closed last week.
Earnings Whispers
Our proven model does not conclusively predict an earnings beat for Amgen this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that is not the case here.
Earnings ESP: Amgen’s Earnings ESP is -4.62% as the Zacks Consensus Estimate is pegged at $4.00 and the Most Accurate Estimate is lower at $3.81. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Amgen has a Zacks Rank #3.
Stocks to Consider
Here are some large drug/biotech stocks that have the right combination of elements to beat on earnings this time around:
Gilead Sciences (GILD - Free Report) has an Earnings ESP of +6.00% and a Zacks Rank #3.
Zacks Top 10 Stocks for 2021
In addition to the stocks discussed above, would you like to know about our 10 best buy-and-hold tickers for the entirety of 2021?
Last year's 2020 Zacks Top 10 Stocks portfolio returned gains as high as +386.8%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Image: Bigstock
Amgen (AMGN) to Report Q1 Earnings: What's in the Cards?
Amgen, Inc. (AMGN - Free Report) will report first-quarter 2021 results on Apr 27, after market close. In the last reported quarter, the company delivered an earnings surprise of 13.39%.
The large biotech’s performance has been pretty impressive, with earnings beating estimates in each of the trailing four quarters. The company delivered a four-quarter earnings surprise of 13.54%, on average.
Amgen Inc. Price and EPS Surprise
Amgen Inc. price-eps-surprise | Amgen Inc. Quote
Amgen’s stock has risen 11% this year so far against a decrease of 2% for the industry.
Factors to Consider
Historically, the first quarter of 2021 represents the lowest product sales quarter of the year for Amgen as U.S. patients work through deductibles, especially for products, including Enbrel, Otezla and Aimovig.
The first quarter of 2020 had benefited from roughly $100 million in inventory build due to COVID-19, which was absent in the first quarter of 2021. Nonetheless, in the first quarter, volume growth from Prolia, Otezla Repatha, Evenity, Aimovig, and Amgen’s biosimilars portfolio is expected to have been partially offset by biosimilar/generic competition for mature drugs and accelerating erosion in U.S. Parsabiv sales due to changes in reimbursement rules for the drug.
In the second half of 2020, Amgen experienced recovery from peak impact of the COVID-19 pandemic as physician interaction and prescription trends of several drugs like Prolia and Xgeva improved. Though the recovery is expected to have continued in the first quarter, the impact of rising COVID-19 infection rates is to be seen.
Meanwhile, higher volumes may have benefited sales of Blincyto, Nplate, Repatha, Vectibix Otezla and Evenity.
New patient share helped by encouraging uptake for combination use of Kyprolis plus Darzalex and dexamethasone (based on CADOR study data) might have pulled up sales of Kyprolis. Parsabiv sales in the first quarter are expected to be the lowest of the year as customers depleted inventory build in the second half of 2020.
The Zacks Consensus Estimate for Prolia is $701 million, Xgeva is $485 million, Blincyto is $103 million, Parsabiv is $116 million, Repatha is $244 million, Kyprolis is $277 million and Otezla is $585 million.
Also, increasing branded and generic competition for its legacy products like Enbrel, Aranesp, Epogen, Neupogen, Neulasta and Sensipar are likely to have hurt the top line. In the first quarter of 2020, Enbrel benefited from approximately $115 of favorable changes to estimated sales deductions, which will not reflect and thereby hurt results of the first quarter of 2021. The Zacks Consensus Estimate for Enbrel is $1.10 billion.
For biosimilars, volume growth may have been partially offset by lower prices due to increased competition. Market expansion and volume growth are expected to benefit Mvasi’s (biosimilar of Roche’s [(RHHBY - Free Report) ] Avastin) sales while lower prices due to increased competition may hurt sales. Kanjinti’s (Amgen’s biosimilar of Roche’s Herceptin) sequential sales may have declined, similar to the fourth quarter of 2020, as volume gains might have been offset by price declines
Meanwhile, in December, the FDA approved Riabni, a biosimilar to Roche’s Rituxan. Amgen may report first sales from the biosimilar product in the first quarter.
Investments in innovation, launch of new products and digitization efforts are expected to have increased operating expenses in the first quarter.
Key Development in the Quarter
In March, Amgen announced an agreement to acquire small biotech, Five Prime Therapeutics or $38.00 per share in cash (an equity value of approximately $1.9 billion) to strengthen its oncology portfolio. The acquisition will add the latter’s lead pipeline candidate, bemarituzumab, a first-in-class, phase III ready, anti-FGFR2b antibody, to its portfolio. The transaction closed last week.
Earnings Whispers
Our proven model does not conclusively predict an earnings beat for Amgen this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that is not the case here.
Earnings ESP: Amgen’s Earnings ESP is -4.62% as the Zacks Consensus Estimate is pegged at $4.00 and the Most Accurate Estimate is lower at $3.81. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Amgen has a Zacks Rank #3.
Stocks to Consider
Here are some large drug/biotech stocks that have the right combination of elements to beat on earnings this time around:
AstraZeneca (AZN - Free Report) with an Earnings ESP of +5.26% and a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
Gilead Sciences (GILD - Free Report) has an Earnings ESP of +6.00% and a Zacks Rank #3.
Zacks Top 10 Stocks for 2021
In addition to the stocks discussed above, would you like to know about our 10 best buy-and-hold tickers for the entirety of 2021?
Last year's 2020 Zacks Top 10 Stocks portfolio returned gains as high as +386.8%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Access Zacks Top 10 Stocks for 2021 today >>